{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:08:11Z","timestamp":1784045291007,"version":"3.55.0"},"reference-count":184,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure with preserved ejection fraction (HFpEF) is a major cause of cardiovascular morbidity and mortality globally. Despite significant research, the pathophysiological mechanisms underlying this complex condition remain poorly defined. Recently, the venous system has emerged as an underrecognized yet critical contributor to HFpEF pathogenesis, functioning as the primary capacitance system and a determinant of central venous pressure. Evidence suggests an imbalance between endothelial-derived relaxing and contractile factors (EDRF\/EDCF), leading to venous endothelial dysfunction, elevated venous tone, and increased mean circulatory filling pressure, all factors that contribute to ventricular\u2013vascular mismatch. This review synthesizes current literature on the vasoactive effects of EDRF and EDCF in the venous vs. arterial systems, in both preclinical and clinical models, and examines how HFpEF therapies may target these pathways. While preclinical models demonstrate the vasoactivity of these mediators in veins of healthy and hypertensive animals, studies investigating its effects in validated HFpEF models are lacking, prompting further research. Furthermore, clinical studies should also prioritize functional assessments and venous-specific endpoints, including direct measures of venous compliance, to better guide therapeutic strategies for HFpEF.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvag024","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:45:12Z","timestamp":1779882312000},"page":"292-308","source":"Crossref","is-referenced-by-count":0,"title":["Venous vascular pharmacology: how does it contribute to heart failure with preserved ejection fraction?"],"prefix":"10.1093","volume":"12","author":[{"given":"Justin","family":"Lineham","sequence":"first","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne 3004 ,","place":["Australia"]},{"name":"Heart Failure Research Group, Baker Heart and Diabetes Institute , Melbourne 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Dagan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne 3004 ,","place":["Australia"]},{"name":"Heart Failure Research Group, Baker Heart and Diabetes Institute , Melbourne 3004 ,","place":["Australia"]},{"name":"Monash Alfred Baker Centre for Cardiovascular Research , Monash University, Melbourne 3004 ,","place":["Australia"]},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Melbourne 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[{"name":"Heart Failure Research Group, Baker Heart and Diabetes Institute , Melbourne 3004 ,","place":["Australia"]},{"name":"Monash Alfred Baker Centre for Cardiovascular Research , Monash University, Melbourne 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-0372","authenticated-orcid":false,"given":"David M","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , 55 Commercial Rd, Melbourne 3004 ,","place":["Australia"]},{"name":"Heart Failure Research Group, Baker Heart and Diabetes Institute , Melbourne 3004 ,","place":["Australia"]},{"name":"Monash Alfred Baker Centre for Cardiovascular Research , Monash University, Melbourne 3004 ,","place":["Australia"]},{"name":"Faculty of Medicine, Nursing and Health Sciences, Monash University , Melbourne 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026071411414506500_pvag024-B1","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.jacc.2022.02.050","article-title":"Venous tone and stressed blood volume in heart failure: JACC review topic of the week","volume":"79","author":"Fudim","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026071411414506500_pvag024-B2","doi-asserted-by":"publisher","first-page":"H1364","DOI":"10.1152\/ajpheart.00004.2014","article-title":"Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"306","author":"Kitzman","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10741-012-9353-8","article-title":"Metabolic and structural impairment of skeletal muscle in heart failure","volume":"18","author":"Zizola","year":"2013","journal-title":"Heart Fail Rev"},{"key":"2026071411414506500_pvag024-B4","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1161\/01.Cir.0000165133.84978.E2","article-title":"Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism","volume":"111","author":"Rodr\u00edguez-Vita","year":"2005","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-323-88433-4.00012-7","volume-title":"Genesis, Pathophysiology and Management of Venous and Lymphatic Disorders","author":"Radhakrishnan","year":"2022"},{"key":"2026071411414506500_pvag024-B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","article-title":"Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms","volume":"3","author":"Stirban","year":"2014","journal-title":"Mol Metab"},{"key":"2026071411414506500_pvag024-B7","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20220285","article-title":"Venous endothelial function in cardiovascular disease","volume":"42","author":"Dardi","year":"2022","journal-title":"Biosci Rep"},{"key":"2026071411414506500_pvag024-B8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/01.cir.94.6.1298","article-title":"Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients","volume":"94","author":"Taddei","year":"1996","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B9","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1097\/00005344-199204002-00054","article-title":"Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension","volume":"20","author":"Taddei","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1573346","article-title":"Evolving role of myocardial fibrosis in heart failure with preserved ejection fraction","volume":"12","author":"Malik","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"2026071411414506500_pvag024-B11","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.jacc.2019.01.072","article-title":"Exercise intolerance in patients with heart failure: JACC state-of-the-art review","volume":"73","author":"Del Buono","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026071411414506500_pvag024-B12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","volume":"288","author":"Furchgott","year":"1980","journal-title":"Nature"},{"key":"2026071411414506500_pvag024-B13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphys.2018.00382","article-title":"Cardiac remodeling: endothelial cells have more to say than just NO","volume":"9","author":"Segers","year":"2018","journal-title":"Front Physiol"},{"key":"2026071411414506500_pvag024-B14","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"Ignarro","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026071411414506500_pvag024-B15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/327524a0","article-title":"Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor","volume":"327","author":"Palmer","year":"1987","journal-title":"Nature"},{"key":"2026071411414506500_pvag024-B16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/s0005-2728(99)00024-9","article-title":"Guanylate cyclase and the.NO\/cGMP signaling pathway","volume":"1411","author":"Denninger","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"2026071411414506500_pvag024-B17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1152\/physrev.00015.2023","article-title":"Phosphodiesterase in heart and vessels: from physiology to diseases","volume":"104","author":"Fu","year":"2024","journal-title":"Physiol Rev"},{"key":"2026071411414506500_pvag024-B18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.cir.101.2.165","article-title":"Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans","volume":"101","author":"Blackman","year":"2000","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/cvr\/23.12.1053","article-title":"Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivo","volume":"23","author":"Vallance","year":"1989","journal-title":"Cardiovasc Res"},{"key":"2026071411414506500_pvag024-B20","doi-asserted-by":"publisher","first-page":"H1034","DOI":"10.1152\/ajpheart.1991.261.4.H1034","article-title":"Hyperpolarization contributes to endothelium-dependent relaxations to acetylcholine in femoral veins of rats","volume":"261","author":"Nagao","year":"1991","journal-title":"Am J Physiol"},{"key":"2026071411414506500_pvag024-B21","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.jvs.2011.10.124","article-title":"Endothelium-dependent nitric oxide and hyperpolarization-mediated venous relaxation pathways in rat inferior vena cava","volume":"55","author":"Raffetto","year":"2012","journal-title":"J Vasc Surg"},{"key":"2026071411414506500_pvag024-B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijcard.2005.01.013","article-title":"Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery","volume":"105","author":"Rakici","year":"2005","journal-title":"Int J Cardiol"},{"key":"2026071411414506500_pvag024-B23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1476-5381.1990.tb14657.x","article-title":"Effects of basal and acetylcholine-induced release of endothelium-derived relaxing factor on contraction to alpha-adrenoceptor agonists in a rabbit artery and corresponding veins","volume":"99","author":"McGrath","year":"1990","journal-title":"Br J Pharmacol"},{"key":"2026071411414506500_pvag024-B24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1476-5381.1990.tb14720.x","article-title":"Simultaneous perfusion of rat isolated superior mesenteric arterial and venous beds: comparison of their vasoconstrictor and vasodilator responses to agonists","volume":"99","author":"Warner","year":"1990","journal-title":"Br J Pharmacol"},{"key":"2026071411414506500_pvag024-B25","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1097\/00005344-198914110-00012","article-title":"Relaxations to SIN-1, nitric oxide, and sodium nitroprusside in canine arteries and veins","volume":"14","author":"Miller","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/sj.bjp.0703700","article-title":"S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery","volume":"131","author":"Sogo","year":"2000","journal-title":"Br J Pharmacol"},{"key":"2026071411414506500_pvag024-B27","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/00005344-200406000-00014","article-title":"Different role of nitric oxide and endothelium-derived hyperpolarizing factor in endothelium-dependent hyperpolarization and relaxation in porcine coronary arterial and venous system","volume":"43","author":"Zhang","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1161\/01.res.68.1.52","article-title":"Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein","volume":"68","author":"Yang","year":"1991","journal-title":"Circ Res"},{"key":"2026071411414506500_pvag024-B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jphs.2024.11.002","article-title":"Different sensitivities of porcine coronary arteries and veins to BAY 60\u20132770, a soluble guanylate cyclase activator","volume":"157","author":"Tawa","year":"2025","journal-title":"J Pharmacol Sci"},{"key":"2026071411414506500_pvag024-B30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4149\/bll_2013_117","article-title":"Cilostazol-induced relaxation of calf cardiac vein and coronary artery during cooling","volume":"114","author":"Nurullahoglu-Atalik","year":"2013","journal-title":"Bratisl Lek Listy"},{"key":"2026071411414506500_pvag024-B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14175928","article-title":"Decreased endogenous nitric oxide production in patients with acute decompensated heart failure with preserved ejection fraction","volume":"14","author":"Falls","year":"2025","journal-title":"J Clin Med"},{"key":"2026071411414506500_pvag024-B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.879214","article-title":"Mimicking metabolic disturbance in establishing animal models of heart failure with preserved ejection fraction","volume":"13","author":"Li","year":"2022","journal-title":"Front Physiol"},{"key":"2026071411414506500_pvag024-B33","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1001\/jama.2018.14852","article-title":"Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial","volume":"320","author":"Borlaug","year":"2018","journal-title":"JAMA"},{"key":"2026071411414506500_pvag024-B34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/circulationaha.114.012957","article-title":"Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction","volume":"131","author":"Zamani","year":"2015","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B35","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ejhf.2093","article-title":"Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction","volume":"23","author":"Reddy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026071411414506500_pvag024-B36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jchf.2015.12.013","article-title":"One week of daily dosing with beetroot juice improves submaximal endurance and blood pressure in older patients with heart failure and preserved ejection fraction","volume":"4","author":"Eggebeen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026071411414506500_pvag024-B37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41569-024-01067-1","article-title":"Pathophysiological insights into HFpEF from studies of human cardiac tissue","volume":"22","author":"Fayyaz","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"2026071411414506500_pvag024-B38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/circulationaha.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B39","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"2026071411414506500_pvag024-B40","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"2026071411414506500_pvag024-B41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1124\/jpet.105.094763","article-title":"Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation","volume":"317","author":"MacPherson","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2026071411414506500_pvag024-B42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/shk.0000000000002277","article-title":"Soluble guanylate cyclase stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"61","author":"Zhao","year":"2024","journal-title":"Shock"},{"key":"2026071411414506500_pvag024-B43","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"2026071411414506500_pvag024-B44","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2026071411414506500_pvag024-B45","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol Rev"},{"key":"2026071411414506500_pvag024-B46","doi-asserted-by":"publisher","first-page":"3a","DOI":"10.1016\/s0002-9149(99)80377-4","article-title":"Pharmacodynamic profile of prostacyclin","volume":"75","author":"Vane","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026071411414506500_pvag024-B47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/s1078-5884(03)00385-x","article-title":"Prostacyclin: a vascular mediator","volume":"26","author":"Vane","year":"2003","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026071411414506500_pvag024-B48","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"2026071411414506500_pvag024-B49","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1073\/pnas.74.9.3922","article-title":"Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells","volume":"74","author":"Weksler","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026071411414506500_pvag024-B50","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.yexcr.2017.11.016","article-title":"Venous endothelium reactivity to angiotensin II: a study in primary endothelial cultures of rat vena cava and portal vein","volume":"362","author":"Trindade","year":"2018","journal-title":"Exp Cell Res"},{"key":"2026071411414506500_pvag024-B51","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1161\/01.cir.67.6.1174","article-title":"Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease","volume":"67","author":"FitzGerald","year":"1983","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B52","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1016\/S0021-9258(19)81600-9","article-title":"The stimulatory G protein of adenylyl cyclase, Gs, also stimulates dihydropyridine-sensitive Ca2+ channels. Evidence for direct regulation independent of phosphorylation by cAMP-dependent protein kinase or stimulation by a dihydropyridine agonist","volume":"263","author":"Yatani","year":"1988","journal-title":"J Biol Chem"},{"key":"2026071411414506500_pvag024-B53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bcp.2018.02.012","article-title":"Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease","volume":"153","author":"Liu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"2026071411414506500_pvag024-B54","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1113\/jphysiol.2007.134338","article-title":"Differences in sympathetic neuroeffector transmission to rat mesenteric arteries and veins as probed by in vitro continuous amperometry and video imaging","volume":"584","author":"Park","year":"2007","journal-title":"J Physiol"},{"key":"2026071411414506500_pvag024-B55","doi-asserted-by":"publisher","first-page":"H1501","DOI":"10.1152\/ajpheart.1993.265.5.H1501","article-title":"Characterization of alpha-adrenoceptor gene expression in arterial and venous smooth muscle","volume":"265","author":"Ping","year":"1993","journal-title":"Am J Physiol"},{"key":"2026071411414506500_pvag024-B56","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/00004872-200204000-00024","article-title":"Endothelin receptor function in mesenteric veins from deoxycorticosterone acetate salt-hypertensive rats","volume":"20","author":"Johnson","year":"2002","journal-title":"J Hypertens"},{"key":"2026071411414506500_pvag024-B57","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.peptides.2010.10.010","article-title":"Involvement of the AT1 receptor in the venoconstriction induced by angiotensin II in both the inferior vena cava and femoral vein","volume":"32","author":"da Silva","year":"2011","journal-title":"Peptides"},{"key":"2026071411414506500_pvag024-B58","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.93.19.10417","article-title":"Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress","volume":"93","author":"Topper","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026071411414506500_pvag024-B59","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1126\/science.3883488","article-title":"Flow effects on prostacyclin production by cultured human endothelial cells","volume":"227","author":"Frangos","year":"1985","journal-title":"Science"},{"key":"2026071411414506500_pvag024-B60","doi-asserted-by":"publisher","first-page":"C499","DOI":"10.1152\/ajpcell.00122.2003","article-title":"Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases","volume":"285","author":"Boo","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026071411414506500_pvag024-B61","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.1375","article-title":"Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study","volume":"21","author":"Beghetti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026071411414506500_pvag024-B62","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026071411414506500_pvag024-B63","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1161\/atvbaha.119.313883","article-title":"Treatment with treprostinil and metformin normalizes hyperglycemia and improves cardiac function in pulmonary hypertension associated with heart failure with preserved ejection fraction","volume":"40","author":"Wang","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071411414506500_pvag024-B64","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bcp.14484","article-title":"Iloprost and exercise haemodynamics in heart failure with preserved ejection fraction\u2014the ILO-HOPE randomised controlled trial","volume":"87","author":"Wu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026071411414506500_pvag024-B65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1249\/mss.0000000000002145","article-title":"Inhaled prostacyclin on exercise echocardiographic cardiac function in preserved ejection fraction heart failure","volume":"52","author":"Huang","year":"2020","journal-title":"Med Sci Sports Exerc"},{"key":"2026071411414506500_pvag024-B66","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1086\/679725","article-title":"Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost","volume":"5","author":"Grossman","year":"2015","journal-title":"Pulm Circ"},{"key":"2026071411414506500_pvag024-B67","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00424-010-0804-6","article-title":"Epoxyeicosatrienoic acids and endothelium-dependent responses","volume":"459","author":"Campbell","year":"2010","journal-title":"Pflugers Arch"},{"key":"2026071411414506500_pvag024-B68","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.yjmcc.2005.07.007","article-title":"Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans","volume":"39","author":"Shimokawa","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"2026071411414506500_pvag024-B69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/24388","article-title":"K+ is an endothelium-derived hyperpolarizing factor in rat arteries","volume":"396","author":"Edwards","year":"1998","journal-title":"Nature"},{"key":"2026071411414506500_pvag024-B70","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1161\/01.res.87.6.474","article-title":"Electrical coupling between endothelial cells and smooth muscle cells in hamster feed arteries: role in vasomotor control","volume":"87","author":"Emerson","year":"2000","journal-title":"Circ Res"},{"key":"2026071411414506500_pvag024-B71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-3-319-20825-1_14","article-title":"Endocannabinoids and the cardiovascular system in health and disease","volume":"231","author":"O\u2019Sullivan","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"2026071411414506500_pvag024-B72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/apha.12649","article-title":"EDH: endothelium-dependent hyperpolarization and microvascular signalling","volume":"219","author":"Garland","year":"2017","journal-title":"Acta Physiol (Oxf)"},{"key":"2026071411414506500_pvag024-B73","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1161\/01.ATV.0000217611.81085.c5","article-title":"Endothelium-derived hyperpolarizing factor: where are we now?","volume":"26","author":"F\u00e9l\u00e9tou","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071411414506500_pvag024-B74","first-page":"5","article-title":"Reactivity of internal mammary artery and saphenous vein used in human myocardial revascularization: studies with endogenous vasoconstrictors and vasodilators","volume":"122","author":"Huidobro-Toro","year":"1994","journal-title":"Rev Med Chil"},{"key":"2026071411414506500_pvag024-B75","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/0895-7061(95)00435-1","article-title":"Relaxant effect of human brain natriuretic peptide on human artery and vein tissue","volume":"9","author":"Protter","year":"1996","journal-title":"Am J Hypertens"},{"key":"2026071411414506500_pvag024-B76","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/cs0740207","article-title":"Direct effect of alpha-human atrial natriuretic peptide on human vasculature in vivo and in vitro","volume":"74","author":"Hughes","year":"1988","journal-title":"Clin Sci (Lond)"},{"key":"2026071411414506500_pvag024-B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112629","article-title":"Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications","volume":"20","author":"Tanase","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026071411414506500_pvag024-B78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.hfc.2017.08.002","article-title":"Natriuretic peptides in heart failure: atrial and B-type natriuretic peptides","volume":"14","author":"Maisel","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2026071411414506500_pvag024-B79","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1161\/hypertensionaha.121.18114","article-title":"Endothelial natriuretic peptide receptor 1 play crucial role for acute and chronic blood pressure regulation by atrial natriuretic peptide","volume":"79","author":"Tokudome","year":"2022","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B80","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1536\/ihj.30.443","article-title":"Lack of venodilative activity of alpha human atrial natriuretic polypeptide in patients with congestive heart failure","volume":"30","author":"Ikenouchi","year":"1989","journal-title":"Jpn Heart J"},{"key":"2026071411414506500_pvag024-B81","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1161\/01.Atv.0000084826.86349.1d","article-title":"Atrial natriuretic peptide regulates regional vascular volume and venous tone in humans","volume":"23","author":"Schmitt","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071411414506500_pvag024-B82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10641968609074765","article-title":"Aging and vasodilation to atrial peptides","volume":"8","author":"Emmick","year":"1986","journal-title":"Clin Exp Hypertens A"},{"key":"2026071411414506500_pvag024-B83","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/01.ATV.zhq0504.7914","article-title":"Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure","volume":"24","author":"Schmitt","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071411414506500_pvag024-B84","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/s0735-1097(01)01142-1","article-title":"Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction","volume":"37","author":"Nightingale","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026071411414506500_pvag024-B85","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/01.cir.83.1.191","article-title":"Mechanisms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart failure","volume":"83","author":"M\u00fcnzel","year":"1991","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B86","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/00005344-199906000-00016","article-title":"Long-term administration of atrial natriuretic peptide in patients with acute heart failure","volume":"33","author":"Kitashiro","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B87","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.cir.86.4.1089","article-title":"Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure","volume":"86","author":"M\u00fcnzel","year":"1992","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1536\/ihj.29.143","article-title":"Acute hemodynamic effects of alpha human atrial natriuretic polypeptide in patients with congestive heart failure","volume":"29","author":"Serizawa","year":"1988","journal-title":"Jpn Heart J"},{"key":"2026071411414506500_pvag024-B89","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1586\/erc.12.31","article-title":"The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure","volume":"10","author":"Dandamudi","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026071411414506500_pvag024-B90","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.115.002593","article-title":"Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF trial (renal optimization strategies evaluation in acute heart failure)","volume":"9","author":"Wan","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026071411414506500_pvag024-B91","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.cardfail.2013.06.221","article-title":"Nesiritide prolongs hospital length of stay in acute decompensated heart failure with preserved ejection fraction","volume":"19","author":"Patel","year":"2013","journal-title":"J Card Fail"},{"key":"2026071411414506500_pvag024-B92","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/ehf2.13770","article-title":"Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure","volume":"9","author":"Nogi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026071411414506500_pvag024-B93","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.cardfail.2015.05.007","article-title":"Carperitide is associated with increased in-hospital mortality in acute heart failure: a propensity score-matched analysis","volume":"21","author":"Matsue","year":"2015","journal-title":"J Card Fail"},{"key":"2026071411414506500_pvag024-B94","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/ehjacc\/zuae140","article-title":"Effect of low-dose administration of carperitide for acute heart failure: the LASCAR-AHF trial","volume":"14","author":"Honda","year":"2025","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026071411414506500_pvag024-B95","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/s0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"2026071411414506500_pvag024-B96","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026071411414506500_pvag024-B97","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0022-5223(19)34803-2","article-title":"Responses of human gastroepiploic arteries to vasoactive substances: comparison with responses of internal mammary arteries and saphenous veins","volume":"104","author":"Ochiai","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026071411414506500_pvag024-B98","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/01.cir.80.4.1041","article-title":"Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein","volume":"80","author":"Yang","year":"1989","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B99","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0140-6736(91)91571-b","article-title":"Different interactions of platelets with arterial and venous coronary bypass vessels","volume":"337","author":"Yang","year":"1991","journal-title":"Lancet"},{"key":"2026071411414506500_pvag024-B100","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/rr195","article-title":"Signaling and regulation of G protein-coupled receptors in airway smooth muscle","volume":"4","author":"Billington","year":"2003","journal-title":"Respir Res"},{"key":"2026071411414506500_pvag024-B101","doi-asserted-by":"crossref","DOI":"10.4199\/C00012ED1V01Y201005ISP007","volume-title":"Regulation of Vascular Smooth Muscle Function","author":"Khalil","year":"2010"},{"key":"2026071411414506500_pvag024-B102","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1161\/01.hyp.18.2.165","article-title":"Cellular mechanism of endothelin-1 release by angiotensin and vasopressin","volume":"18","author":"Emori","year":"1991","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B103","doi-asserted-by":"publisher","first-page":"H729","DOI":"10.1152\/ajpheart.00388.2004","article-title":"Endothelin in the splanchnic vascular bed of DOCA-salt hypertensive rats","volume":"288","author":"Wang","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B104","doi-asserted-by":"publisher","first-page":"H1115","DOI":"10.1152\/ajpheart.00086.2005","article-title":"Endothelin-1-induced contraction in veins is independent of hydrogen peroxide","volume":"289","author":"Thakali","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B105","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/01.Hyp.0000084853.47326.F2","article-title":"NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension","volume":"42","author":"Li","year":"2003","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B106","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1161\/01.cir.0000051459.74466.46","article-title":"Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension","volume":"107","author":"Li","year":"2003","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B107","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.hyp.21.3.294","article-title":"Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats","volume":"21","author":"Larivi\u00e8re","year":"1993","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B108","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1139\/y95-050","article-title":"Endothelin-1 expression in blood vessels of DOCA-salt hypertensive rats treated with the combined ETA\/ETB endothelin receptor antagonist bosentan","volume":"73","author":"Larivi\u00e8re","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"2026071411414506500_pvag024-B109","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/00005344-199404000-00009","article-title":"Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins","volume":"23","author":"Opgaard","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B110","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1172\/jci117470","article-title":"Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1","volume":"94","author":"Haynes","year":"1994","journal-title":"J Clin Invest"},{"key":"2026071411414506500_pvag024-B111","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1124\/jpet.108.145953","article-title":"Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein","volume":"329","author":"Tykocki","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2026071411414506500_pvag024-B112","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1172\/jci116338","article-title":"Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells","volume":"91","author":"Hirata","year":"1993","journal-title":"J Clin Invest"},{"key":"2026071411414506500_pvag024-B113","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1254\/jphs.12r01cr","article-title":"Pathophysiological roles of endothelin receptors in cardiovascular diseases","volume":"119","author":"Ohkita","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"2026071411414506500_pvag024-B114","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease","volume":"41","author":"Kedzierski","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2026071411414506500_pvag024-B115","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.116.003381","article-title":"Dual endothelin-A\/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction","volume":"9","author":"Valero-Munoz","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026071411414506500_pvag024-B116","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/circulationaha.122.063327","article-title":"Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF","volume":"147","author":"Yeoh","year":"2023","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B117","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000501100","article-title":"Endothelin 1 is associated with heart failure hospitalization and long-term mortality in patients with heart failure with preserved ejection fraction and pulmonary hypertension","volume":"143","author":"Chowdhury","year":"2019","journal-title":"Cardiology"},{"key":"2026071411414506500_pvag024-B118","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jchf.2013.12.002","article-title":"Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction","volume":"2","author":"Zile","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026071411414506500_pvag024-B119","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.123.011381","article-title":"Macitentan for heart failure with preserved or mildly reduced ejection fraction and pulmonary vascular disease: results of the SERENADE randomized clinical trial and open-label extension study","volume":"18","author":"Shah","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026071411414506500_pvag024-B120","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.hlc.2016.09.004","article-title":"Pilot study of endothelin receptor blockade in heart failure with diastolic dysfunction and pulmonary hypertension (BADDHY-trial)","volume":"26","author":"Koller","year":"2017","journal-title":"Heart Lung Circ"},{"key":"2026071411414506500_pvag024-B121","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/01.Hyp.0000070958.39174.7e","article-title":"Functional role of ETB receptors in the renal medulla","volume":"41","author":"Vassileva","year":"2003","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B122","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/s0003-4975(01)03605-0","article-title":"Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins","volume":"73","author":"Ko","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"2026071411414506500_pvag024-B123","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1253\/circj.cj-13-0397","article-title":"Rho-kinase activation in patients with heart failure","volume":"77","author":"Do e","year":"2013","journal-title":"Circ J"},{"key":"2026071411414506500_pvag024-B124","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1161\/circulationaha.105.584623","article-title":"Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+\/- haploinsufficient mice","volume":"112","author":"Rikitake","year":"2005","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B125","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1253\/circj.CJ-16-0433","article-title":"Rho kinases and cardiac remodeling","volume":"80","author":"Shimizu","year":"2016","journal-title":"Circ J"},{"key":"2026071411414506500_pvag024-B126","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/FJC.0b013e31816533b7","article-title":"Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats","volume":"51","author":"Fukui","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B127","doi-asserted-by":"publisher","first-page":"H1804","DOI":"10.1152\/ajpheart.01078.2007","article-title":"Effects of a rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction","volume":"294","author":"Phrommintikul","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B128","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1161\/hy1201.096541","article-title":"Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans","volume":"38","author":"Masumoto","year":"2001","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B129","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1253\/circj.cj-13-0443","article-title":"Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension","volume":"77","author":"Fukumoto","year":"2013","journal-title":"Circ J"},{"key":"2026071411414506500_pvag024-B130","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1253\/circj.CJ-14-1015","article-title":"Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects","volume":"79","author":"Xiao","year":"2015","journal-title":"Circ J"},{"key":"2026071411414506500_pvag024-B131","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1161\/01.RES.0000251668.39526.c7","article-title":"Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease","volume":"99","author":"Nohria","year":"2006","journal-title":"Circ Res"},{"key":"2026071411414506500_pvag024-B132","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/00005344-200211000-00013","article-title":"Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study","volume":"40","author":"Shimokawa","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026071411414506500_pvag024-B133","doi-asserted-by":"publisher","first-page":"H985","DOI":"10.1152\/ajpheart.00292.2006","article-title":"Endothelial dysfunction: a multifaceted disorder (the wiggers award lecture)","volume":"291","author":"F\u00e9l\u00e9tou","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B134","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1476-5381.2009.00240.x","article-title":"Endothelium-dependent contractions and endothelial dysfunction in human hypertension","volume":"157","author":"Versari","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2026071411414506500_pvag024-B135","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1113\/jphysiol.2008.161430","article-title":"Endothelium-dependent contractions: when a good guy turns bad!","volume":"586","author":"Vanhoutte","year":"2008","journal-title":"J Physiol"},{"key":"2026071411414506500_pvag024-B136","volume-title":"StatPearls","author":"Rucker","year":"2022"},{"key":"2026071411414506500_pvag024-B137","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1139\/y99-063","article-title":"Functional comparison of the human isolated femoral artery, internal mammary artery, gastroepiploic artery, and saphenous vein","volume":"77","author":"Cracowski","year":"1999","journal-title":"Can J Physiol Pharmacol"},{"key":"2026071411414506500_pvag024-B138","doi-asserted-by":"publisher","first-page":"L825","DOI":"10.1152\/ajplung.00177.2005","article-title":"Cellular mechanisms of thromboxane A2-mediated contraction in pulmonary veins","volume":"289","author":"Ding","year":"2005","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026071411414506500_pvag024-B139","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood-2006-08-044990","article-title":"Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice","volume":"109","author":"Cyrus","year":"2007","journal-title":"Blood"},{"key":"2026071411414506500_pvag024-B140","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1152\/jappl.2000.89.6.2268","article-title":"Pharmacological characterization of vasomotor activity of human musculocutaneous perforator artery and vein","volume":"89","author":"Zhang","year":"2000","journal-title":"J Appl Physiol (1985)"},{"key":"2026071411414506500_pvag024-B141","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1183\/09031936.93.03060633","article-title":"Acetylcholine and adenosine diphosphate cause endothelium-dependent relaxation of isolated human pulmonary arteries","volume":"3","author":"Dinh Xuan","year":"1990","journal-title":"Eur Respir J"},{"key":"2026071411414506500_pvag024-B142","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-642-29423-5_6","article-title":"Aspirin and other COX-1 inhibitors","volume":"210","author":"Patrono","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"2026071411414506500_pvag024-B143","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1093\/eurheartj\/ehae324","article-title":"Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease","volume":"45","author":"Patrono","year":"2024","journal-title":"Eur Heart J"},{"key":"2026071411414506500_pvag024-B144","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2217\/clp.10.11","article-title":"Thromboxane and the thromboxane receptor in cardiovascular disease","volume":"5","author":"Smyth","year":"2010","journal-title":"Clin Lipidol"},{"key":"2026071411414506500_pvag024-B145","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","article-title":"Heart failure with preserved ejection fraction: a review","volume":"329","author":"Redfield","year":"2023","journal-title":"JAMA"},{"key":"2026071411414506500_pvag024-B146","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026071411414506500_pvag024-B147","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13111330","article-title":"Mitochondrial reactive oxygen species dysregulation in heart failure with preserved ejection fraction: a fraction of the whole","volume":"13","author":"Martinez","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"2026071411414506500_pvag024-B148","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1161\/01.hyp.0000018041.48432.b5","article-title":"Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels","volume":"39","author":"Guzik","year":"2002","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B149","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1161\/01.RES.0000269183.13937.e8","article-title":"Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upregulation of nuclear factor-kappaB","volume":"100","author":"Donato","year":"2007","journal-title":"Circ Res"},{"key":"2026071411414506500_pvag024-B150","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/hypertensionaha.110.165100","article-title":"Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly","volume":"57","author":"Vanhoutte","year":"2011","journal-title":"Hypertension"},{"key":"2026071411414506500_pvag024-B151","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/circulationaha.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B152","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0014-2999(02)02587-6","article-title":"The role of angiotensin II in hypertension due to adenosine receptors blockade","volume":"455","author":"Morato","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"2026071411414506500_pvag024-B153","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/s0741-5214(97)70297-0","article-title":"Endothelium-dependent relaxation of human saphenous veins in response to vasopressin and desmopressin","volume":"25","author":"Aldasoro","year":"1997","journal-title":"J Vasc Surg"},{"key":"2026071411414506500_pvag024-B154","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1476-5381.1994.tb17005.x","article-title":"Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin","volume":"113","author":"Mart\u00ednez","year":"1994","journal-title":"Br J Pharmacol"},{"key":"2026071411414506500_pvag024-B155","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jacc.2010.12.044","article-title":"Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy","volume":"58","author":"Dai","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026071411414506500_pvag024-B156","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bcp.2012.12.021","article-title":"L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-\u03b3 expression","volume":"85","author":"Zambrano","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2026071411414506500_pvag024-B157","doi-asserted-by":"publisher","first-page":"H1720","DOI":"10.1152\/ajpheart.00339.2015","article-title":"N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy","volume":"309","author":"Wilder","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B158","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s11845-021-02829-3","article-title":"Oral N-acetylcysteine as an adjunct to standard medical therapy improved heart function in cases with stable class II and III systolic heart failure","volume":"191","author":"Yazdi","year":"2022","journal-title":"Ir J Med Sci"},{"key":"2026071411414506500_pvag024-B159","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3109\/07853890.2010.543920","article-title":"Oxidative stress and endothelial dysfunction: therapeutic implications","volume":"43","author":"Gori","year":"2011","journal-title":"Ann Med"},{"key":"2026071411414506500_pvag024-B160","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s11897-021-00511-4","article-title":"Selenium, selenoproteins, and heart failure: current knowledge and future perspective","volume":"18","author":"Al-Mubarak","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"2026071411414506500_pvag024-B161","doi-asserted-by":"publisher","DOI":"10.3390\/nu14061284","article-title":"\u03b2-Carotene supplementation and risk of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Yang","year":"2022","journal-title":"Nutrients"},{"key":"2026071411414506500_pvag024-B162","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/s0891-5849(02)00956-5","article-title":"Structure and function of xanthine oxidoreductase: where are we now?","volume":"33","author":"Harrison","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"2026071411414506500_pvag024-B163","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/vhrm.s4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"George","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"2026071411414506500_pvag024-B164","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/01.cir.0000056762.69302.46","article-title":"Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation","volume":"107","author":"Spiekermann","year":"2003","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B165","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1006\/jmcc.2000.1240","article-title":"Enhanced expression and activity of xanthine oxidoreductase in the failing heart","volume":"32","author":"de Jong","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"2026071411414506500_pvag024-B166","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1113\/jphysiol.2003.055913","article-title":"Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications","volume":"555","author":"Berry","year":"2004","journal-title":"J Physiol"},{"key":"2026071411414506500_pvag024-B167","doi-asserted-by":"publisher","first-page":"H1341","DOI":"10.1152\/ajpheart.00569.2008","article-title":"A comparison of reactive oxygen species metabolism in the rat aorta and vena cava: focus on xanthine oxidase","volume":"295","author":"Szasz","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026071411414506500_pvag024-B168","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/01.ATV.0000139011.94634.9d","article-title":"Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins","volume":"24","author":"Guzik","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026071411414506500_pvag024-B169","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1161\/01.cir.0000041431.57222.af","article-title":"Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase","volume":"106","author":"Landmesser","year":"2002","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B170","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/ehf2.12734","article-title":"Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction","volume":"7","author":"Watanabe","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026071411414506500_pvag024-B171","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00392-007-0636-3","article-title":"Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome","volume":"97","author":"Yiginer","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"2026071411414506500_pvag024-B172","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1161\/circulationaha.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B173","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/01.res.51.4.439","article-title":"Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium","volume":"51","author":"De Mey","year":"1982","journal-title":"Circ Res"},{"key":"2026071411414506500_pvag024-B174","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jacbts.2021.11.007","article-title":"Characterization of cardiac sympathetic nervous system and inflammatory activation in HFpEF patients","volume":"7","author":"Kaye","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"2026071411414506500_pvag024-B175","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/s0008-6363(01)00297-8","article-title":"Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin","volume":"51","author":"Kalra","year":"2001","journal-title":"Cardiovasc Res"},{"key":"2026071411414506500_pvag024-B176","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1161\/circheartfailure.112.970012","article-title":"Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial","volume":"6","author":"Lanfear","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026071411414506500_pvag024-B177","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026071411414506500_pvag024-B178","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"2026071411414506500_pvag024-B179","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2024.10.024","article-title":"Translating evidence into practice: managing electrolyte imbalances and iron deficiency in heart failure","volume":"131","author":"Sato","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2026071411414506500_pvag024-B180","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.614","article-title":"Tolvaptan add-on therapy in patients with acute heart failure: a systematic review and meta-analysis","volume":"8","author":"Luo","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"2026071411414506500_pvag024-B181","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"2026071411414506500_pvag024-B182","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ejhf.2001","article-title":"Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a\/V2 receptor antagonist in experimental heart failure","volume":"23","author":"Mondritzki","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026071411414506500_pvag024-B183","doi-asserted-by":"publisher","first-page":"961","DOI":"10.7150\/ijbs.20074","article-title":"Vasopressin mediates the renal damage induced by limited fructose rehydration in recurrently dehydrated rats","volume":"13","author":"Garc\u00eda-Arroyo","year":"2017","journal-title":"Int J Biol Sci"},{"key":"2026071411414506500_pvag024-B184","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cardfail.2020.10.007","article-title":"Dual vasopressin receptor antagonism to improve congestion in patients with acute heart failure: design of the AVANTI trial","volume":"27","author":"Goldsmith","year":"2021","journal-title":"J Card Fail"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag024\/68432166\/pvag024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/4\/292\/68432166\/pvag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/4\/292\/68432166\/pvag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:41:55Z","timestamp":1784043715000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/4\/292\/8698075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":184,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag024","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,29]]}}}